Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): A multicentre randomized controlled trial

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Saadatmand, Sepideh ^a   Rutgers, Emiel J T ^b   Tollenaar, RobAEM ^c   Zonderland, Hermien M ^d   Ausems, MargreetGEM ^e   Keymeulen, KristienBMI ^f   Schlooz Vries, Margreet S ^g   Koppert, Linetta B ^a   Heijnsdijk, Eveline A M ^a   Seynaeve, Caroline ^a   Verhoef, Cees ^a   Oosterwijk, Jan C ^h   Obdeijn, Inge Marie ^a   de Koning, Harry J ^a   Tilanus Linthorst, Madeleine M A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^h UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Breast cancer; Breast density; Cost effectiveness; Familial risk; MRI; Screening

Indexed keywords

ADULT; ARTICLE; BREAST; BREAST CANCER; BREAST DENSITY; BREAST EXAMINATION; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; CLINICAL EXAMINATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FALSE POSITIVE RESULT; FAMILY HISTORY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAMMOGRAPHY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL;

ADULT; BREAST NEOPLASMS; CLINICAL PROTOCOLS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MIDDLE AGED; RISK FACTORS;

EID: 84866780178     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-440     Document Type: Article

References (45)

1. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994, 73(3):643-651. 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5, 8299086.
2. Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age of onset in familial breast cancer as background data for medical surveillance. Br J Cancer 2010, 102(1):42-47. 10.1038/sj.bjc.6605421, 2813740, 19904271.
3. Margolin S, Johansson H, Rutqvist LE, Lindblom A, Fornander T. Family history, and impact on clinical presentation and prognosis, in a population-based breast cancer cohort from the Stockholm County. Fam Cancer 2006, 5(4):309-321. 10.1007/s10689-006-7851-3, 16858627.
4. Sant M, Allemani C, Capocaccia R, Hakulinen T, Aareleid T, Coebergh JW, Coleman MP, Grosclaude P, Martinez C, Bell J, et al. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer 2003, 106(3):416-422. 10.1002/ijc.11226, 12845683.
5. Maurice A, Evans DG, Affen J, Greenhalgh R, Duffy SW, Howell A. Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: Further evidence of benefit. Int J Cancer 2012, 131(2):417-425. 10.1002/ijc.26394, 21898384.
6. teams FHc Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study. Lancet Oncol 2010, 11(12):1127-1134. teams FHc.
7. Tilanus-Linthorst MM, Bartels CC, Obdeijn AI, Oudkerk M. Earlier detection of breast cancer by surveillance of women at familial risk. Eur J Cancer 2000, 36(4):514-519. 10.1016/S0959-8049(99)00337-8, 10717529.
8. Hagen AI, Kvistad KA, Maehle L, Holmen MM, Aase H, Styr B, Vabo A, Apold J, Skaane P, Moller P. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast 2007, 16(4):367-374. 10.1016/j.breast.2007.01.006, 17317184.
9. Kuhl C, Weigel S, Schrading S, Arand B, Bieling H, Konig R, Tombach B, Leutner C, Rieber-Brambs A, Nordhoff D, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol 2010, 28(9):1450-1457. 10.1200/JCO.2009.23.0839, 20177029.
10. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert FJ, Griebsch I, Hoff RJ, Kessar P, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005, 365(9473):1769-1778.
11. Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Loo CE, Wasser MN, Bergers E, Kok T, Muller SH, et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol 2010, 28(36):5265-5273. 10.1200/JCO.2009.27.2294, 21079137.
12. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004, 292(11):1317-1325. 10.1001/jama.292.11.1317, 15367553.
13. van der Velden AP S, Schlooz-Vries MS, Boetes C, Wobbes T. Magnetic resonance imaging of ductal carcinoma in situ: what is its clinical application? A review. Am J Surg 2009, 198(2):262-269. 10.1016/j.amjsurg.2009.01.010, 19375068.
14. Griebsch I, Brown J, Boggis C, Dixon A, Dixon M, Easton D, Eeles R, Evans DG, Gilbert FJ, Hawnaur J, et al. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. Br J Cancer 2006, 95(7):801-810. 10.1038/sj.bjc.6603356, 2360541, 17016484.
15. Lee JM, McMahon PM, Kong CY, Kopans DB, Ryan PD, Ozanne EM, Halpern EF, Gazelle GS. Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers. Radiology 2010, 254(3):793-800. 10.1148/radiol.09091086, 2826703, 20177093.
16. Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006, 295(20):2374-2384. 10.1001/jama.295.20.2374, 16720823.
17. Richtlijn mammacarcinoom , , , http://www.oncoline.nl/uploaded/docs/mammacarcinoom/mammacdiagscr.pdf, .
18. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007, 57(2):75-89. 10.3322/canjclin.57.2.75, 17392385.
19. Kerlikowske K. The mammogram that cried Wolfe. N Engl J Med 2007, 356(3):297-300. 10.1056/NEJMe068244, 17229958.
20. Mitchell G, Antoniou AC, Warren R, Peock S, Brown J, Davies R, Mattison J, Cook M, Warsi I, Evans DG, et al. Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res 2006, 66(3):1866-1872. 10.1158/0008-5472.CAN-05-3368, 16452249.
21. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007, 356(3):227-236. 10.1056/NEJMoa062790, 17229950.
22. Thompson DJ, Leach MO, Kwan-Lim G, Gayther SA, Ramus SJ, Warsi I, Lennard F, Khazen M, Bryant E, Reed S, et al. Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study. Breast Cancer Res 2009, 11(6):R80. 10.1186/bcr2447, 2815542, 19903338.
23. Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, Peacock S, Smazal SF, Maki DD, Julian TB, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007, 356(13):1295-1303. 10.1056/NEJMoa065447, 17392300.
24. Tilanus-Linthorst MM, Obdeijn IM, Hop WC, Causer PA, Leach MO, Warner E, Pointon L, Hill K, Klijn JG, Warren RM, et al. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res 2007, 13(24):7357-7362. 10.1158/1078-0432.CCR-07-0689, 18094417.
25. Checka CM, Chun JE, Schnabel FR, Lee J, Toth H. The relationship of mammographic density and age: implications for breast cancer screening. AJR Am J Roentgenol 2012, 198(3):W292-W295. 10.2214/AJR.10.6049, 22358028.
26. Zonderland HM, Coerkamp EG, Hermans J, van de Vijver MJ, van Voorthuisen AE. Diagnosis of breast cancer: contribution of US as an adjunct to mammography. Radiology 1999, 213(2):413-422.
27. van Asperen CJ, Jonker MA, Jacobi CE, van Diemen-Homan JE, Bakker E, Breuning MH, van Houwelingen JC, de Bock GH. Risk estimation for healthy women from breast cancer families: new insights and new strategies. Cancer Epidemiol Biomarkers Prev 2004, 13(1):87-93. 10.1158/1055-9965.EPI-03-0090, 14744738.
28. Familial breast cancer: the classification and care of women at risk of famial breast cancer in primary, secondary and tertiary care. Clinical Guideline 14 , , , http://www.nice.org.uk/nicemedia/live/10994/30247/30247.pdf, .
29. Mann RM, Kuhl CK, Kinkel K, Boetes C. Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol 2008, 18(7):1307-1318. 10.1007/s00330-008-0863-7, 2441490, 18389253.
30. ACR practice guideline for the performance of contrastenhanced magnetic resonance imaging (MRI) of the breast , , , [http://www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/breast/mri_breast.aspx], .
31. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004, 351(5):427-437. 10.1056/NEJMoa031759, 15282350.
32. Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, Kuhn W, Schild HH. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005, 23(33):8469-8476. 10.1200/JCO.2004.00.4960, 16293877.
33. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008, 148(9):671-679.
34. Kuhl CK, Schrading S, Bieling HB, Wardelmann E, Leutner CC, Koenig R, Kuhn W, Schild HH. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet 2007, 370(9586):485-492. 10.1016/S0140-6736(07)61232-X, 17693177.
35. Eilertsen AL, Karssemeijer N, Skaane P, Qvigstad E, Sandset PM. Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method. BJOG 2008, 115(6):773-779. 10.1111/j.1471-0528.2008.01690.x, 18355366.
36. van Engeland S, Snoeren PR, Huisman H, Boetes C, Karssemeijer N. Volumetric breast density estimation from full-field digital mammograms. IEEE Trans Med Imaging 2006, 25(3):273-282.
37. Boetes C, Stoutjesdijk M. MR imaging in screening women at increased risk for breast cancer. Magn Reson Imaging Clin N Am 2001, 9(2):357-372. vii.
38. de Koning HJ. Mammographic screening: evidence from randomised controlled trials. Ann Oncol 2003, 14(8):1185-1189. 10.1093/annonc/mdg319, 12881373.
39. Groenewoud JH, Pijnappel RM, van den Akker-Van Marle ME, Birnie E, Buijs-van der Woude T, Mali WP, de Koning HJ, Buskens E. Cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open-breast biopsy. Br J Cancer 2004, 90(2):383-392. 10.1038/sj.bjc.6601520, 2409541, 14735181.
40. Rijnsburger AJ, van Oortmarssen GJ, Boer R, Draisma G, To T, Miller AB, de Koning HJ. Mammography benefit in the Canadian National Breast Screening Study-2: a model evaluation. Int J Cancer 2004, 110(5):756-762. 10.1002/ijc.20143, 15146566.
41. (NETB) NETfBcs National evaluation of breast cancer screening in the Netherlands - eleventh evaluation report 2005, Department of Public Health, Erasmus MC, Rotterdam, (NETB) NETfBcs.
42. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005, 353(17):1784-1792. 10.1056/NEJMoa050518, 16251534.
43. Bjurstam N, Bjorneld L, Warwick J, Sala E, Duffy SW, Nystrom L, Walker N, Cahlin E, Eriksson O, Hafstrom LO, et al. The Gothenburg Breast Screening Trial. Cancer 2003, 97(10):2387-2396. 10.1002/cncr.11361, 12733136.
44. Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002, 359(9310):909-919. 10.1016/S0140-6736(02)08020-0, 11918907.
45. Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 2003, 361(9367):1405-1410. 10.1016/S0140-6736(03)13143-1, 12727392.